ClinicalTrials.Veeva

Menu
Q

Quest Clinical Research | San Francisco, CA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Sofosbuvir
Ribavirin
Interferon
Peginterferon
Budigalimab
Daclatasvir
Bevirimat
Valganciclovir
Leronlimab
ABI-H2158

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 89 total trials

A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3

Enrolling
NASH - Nonalcoholic Steatohepatitis
Drug: Placebo
Drug: IVA337

Human immuno-deficiency virus (HIV) is the virus that causes Acquired Immuno-Deficiency Syndrome (AIDS). HIV disease is considered to be a chronic di...

Enrolling
Human Immuno-deficiency Virus (HIV) Disease
Drug: Placebo for Budigalimab
Drug: Budigalimab

This is a first in human (FIH), multi-center, dose-finding, and dose-escalation Phase I clinical study of RO7565020 to investigate the safety and tol...

Enrolling
Chronic Hepatitis B
Drug: RO7565020
Other: Placebo

Participants who receive EBT-101 in a parent protocol will be eligible to participate in this long-term follow-up (LTFU) study (EBT-101-002).

Invitation-only
HIV-1-infection
Biological: EBT-101

The purpose of the study is to evaluate the safety and feasibility of administering SB-728mR-HSPC after conditioning with busulfan.

Active, not recruiting
HIV
Genetic: SB-728mR-HSPC Infusion 3 days following busulfan conditioning

The goals of this clinical study are to learn more about the study drugs, semaglutide (SEMA) with the fixed-dose combination (FDC) of cilofexor/firso...

Active, not recruiting
Nonalcoholic Steatohepatitis
Drug: Cilofexor (CILO)/Firsocostat (FIR)
Drug: PTM SEMA

TMB-365 is a monoclonal antibody that binds to the CD4 receptor. TMB-380, aka VRC-07-523LS is a monoclonal antibody that binds to HIV. Both interfere...

Active, not recruiting
HIV-1-infection
Drug: TMB-365/TMB-380

Trial sponsors

Gilead Sciences logo
A
Bristol-Myers Squibb (BMS) logo
Roche logo
T
AbbVie logo
C
G
S
M

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems